Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Buy dildos and adult toys.
Popular Articles

Fibromyalgia Patients Show Decreases In Gray Matter Intensity
Previous studies have shown that fibromyalgia is associated with reductions in gray matter in parts of the brain, but the exact cause is not known. Using sophisticated brain imaging techniques, researchers from Louisiana State University, writing in The Journal of Pain, found that alterations in levels of the neurotransmitter dopamine might be responsible for gray matter reductions.
buy viagra
Inovio Biomedical To Present At International DNA Vaccine Conference
Inovio Biomedical Corporation (NYSE Amex:INO), a leader in DNA vaccine design, development and delivery, announced today that it will make multiple presentations at the Annual Conference of DNA Vaccines in Asia 2009 being hosted by the International Society of DNA Vaccines July 9 - 10 at the Beijing International Convention Center. The conference, with the theme, "Advancing DNA Vaccine Technology," is co-chaired by David B. Weiner, Ph.D., professor of pathology, University of Pennsylvania School of Medicine, and chairman of Inovio"s scientific advisory board.
News of the day
Adhering To Healthy Lifestyle Habits Associated With Reduced Lifetime Risk Of Heart Failure
Men who exercised regularly, drank moderately, did not smoke, who were not overweight and had a diet that included cereal and fruits and vegetables had a lower lifetime risk of heart failure, according to a study in the July 22/29 issue of JAMA.
Endocrinology

St. Jude Medical Announces Australian TGA Regulatory Approval For Libra Deep Brain Stimulation Systems For Parkinson's Disease

St. Jude Medical, Inc. (NYSE:STJ) announced Australian Therapeutic Goods Administration (TGA) approval of its Libra® and LibraXP™ deep brain stimulation (DBS) systems for treating the symptoms of Parkinson"s disease, a neurological disorder that progressively diminishes a person"s control over his or her movements. Similar to a heart pacemaker, the Libra DBS systems function by delivering mild electrical pulses from an implanted device via thin wires with multiple independent electrodes. The stimulation is targeted to one of three regions in the brain which are involved in muscle control for the symptomatic treatment of Parkinson"s disease. "This approval is an important step forward in bringing our deep brain stimulation systems to a broader market," said Chris Chavez, president of the St. Jude Medical Neuromodulation Division. "We are excited to be able to provide physicians in Australia with these best-in-class deep brain stimulation systems, allowing them to have more capability and control in treating their patients." The Libra and LibraXP neurostimulators are constant current devices that feature the largest battery capacity of any DBS device in their class, which may maximize the time between device replacement procedures. This therapy can be externally programmed by a clinician to meet individual patient needs. An estimated 6.3 million people worldwide live with Parkinson"s disease, according to the European Parkinson"s Disease Association. The disease usually develops in people between the ages of 40 and 70, with an average age of onset of 60 years. Parkinson"s disease affects both men and women in almost equal numbers, although research suggests that men are two to three times more likely to be diagnosed with the disease than women. Parkinson"s Disease Symptoms Parkinson"s disease patients may experience stiffness or rigidity of the arms and legs, slowness or lack of movement, and walking difficulties, in addition to tremor of the hands, arms, legs, jaw or face. These symptoms can make simple, everyday tasks like getting dressed, shaving, eating with utensils and drinking from a glass difficult. Faced with these challenges, Parkinson"s disease patients often have a significant decline in their quality of life. In addition to the TGA approval, the Libra and LibraXP DBS systems have also received the CE Mark approval in Europe. In the U.S., the systems are currently being evaluated in clinical studies for depression, Parkinson"s disease and essential tremor. For more information about these studies, visit http://www.BROADENstudy.com, http://www.PowerOverPD.com and http://www.PowerOverET.com St. Jude Medical


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009